Adicet Bio (ACET)
Adicet Bio on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
522K
Short interest
settlement 2026-10-15
2.3
Days to cover
+1.2 days vs prior
26.8%
Short share of volume
2026-11-02
115
Fails to deliver
settlement 2026-10-14
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ACET is 521,883 shares, up 249,894 shares over the last month. Over the last 48 readings it ranged from 252,663 shares (31 August 2026) to 14,910,583 shares (15 December 2025). The latest reading sits at the bottom of that range. At the reported average volume of 223K shares a day that is 2.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/acet" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 521,883 | +7.5% | 222,595 | 2.34 |
| 2026-09-30 | 485,466 | +78.5% | 439,513 | 1.10 |
| 2026-09-15 | 271,989 | +7.7% | 131,075 | 2.08 |
| 2026-08-31 | 252,663 | -3.7% | 104,508 | 2.42 |
| 2026-08-14 | 262,357 | -33.9% | 82,757 | 3.17 |
| 2026-07-31 | 397,053 | +3.6% | 91,951 | 4.32 |
| 2026-07-15 | 383,174 | -24.2% | 89,405 | 4.29 |
| 2026-06-30 | 505,580 | +0.9% | 96,212 | 5.25 |
| 2026-06-15 | 501,254 | -3.2% | 75,738 | 6.62 |
| 2026-05-29 | 517,922 | -11.9% | 124,748 | 4.15 |
| 2026-05-15 | 587,837 | +6.2% | 103,457 | 5.68 |
| 2026-04-30 | 553,507 | -7.5% | 97,970 | 5.65 |
| 2026-04-15 | 598,458 | -8.8% | 188,812 | 3.17 |
| 2026-03-31 | 656,546 | +3.4% | 110,292 | 5.95 |
| 2026-03-13 | 634,967 | -0.8% | 108,446 | 5.86 |
| 2026-02-27 | 640,053 | -8.9% | 139,887 | 4.58 |
| 2026-02-13 | 702,375 | +1.5% | 232,784 | 3.02 |
| 2026-01-30 | 691,994 | +0.2% | 158,065 | 4.38 |
| 2026-01-15 | 690,550 | +7.4% | 211,119 | 3.27 |
| 2025-12-31 | 642,724 | -95.7% | 206,448 | 3.11 |
| 2025-12-15 | 14,910,583 | +40.3% | 2,860,587 | 5.21 |
| 2025-11-28 | 10,629,486 | +27.6% | 1,803,429 | 5.89 |
| 2025-11-14 | 8,333,397 | +4.6% | 1,673,871 | 4.98 |
| 2025-10-31 | 7,967,144 | +7.8% | 2,169,306 | 3.67 |
| 2025-10-15 | 7,388,636 | +54.5% | 4,008,813 | 1.84 |
| 2025-09-30 | 4,783,686 | +0.1% | 346,724 | 13.80 |
| 2025-09-15 | 4,781,323 | +4.4% | 460,220 | 10.39 |
| 2025-08-29 | 4,578,709 | +2.7% | 600,270 | 7.63 |
| 2025-08-15 | 4,458,758 | +10.6% | 706,763 | 6.31 |
| 2025-07-31 | 4,031,291 | +7.1% | 351,267 | 11.48 |
| 2025-07-15 | 3,764,018 | +13.5% | 419,775 | 8.97 |
| 2025-06-30 | 3,316,444 | +14.7% | 421,322 | 7.87 |
| 2025-06-13 | 2,891,936 | -7.5% | 380,468 | 7.60 |
| 2025-05-30 | 3,125,216 | +32.0% | 638,735 | 4.89 |
| 2025-05-15 | 2,366,713 | +15.9% | 831,582 | 2.85 |
| 2025-04-30 | 2,041,651 | -1.1% | 227,067 | 8.99 |
| 2025-04-15 | 2,064,356 | -27.6% | 736,334 | 2.80 |
| 2025-03-31 | 2,852,042 | +0.6% | 337,420 | 8.45 |
| 2025-03-14 | 2,834,533 | -9.8% | 299,903 | 9.45 |
| 2025-02-28 | 3,142,965 | -16.9% | 581,803 | 5.40 |
| 2025-02-14 | 3,782,288 | +27.2% | 2,880,980 | 1.31 |
| 2025-01-31 | 2,972,465 | -2.7% | 179,924 | 16.52 |
| 2025-01-15 | 3,055,272 | -9.3% | 560,244 | 5.45 |
| 2024-12-31 | 3,369,133 | +0.5% | 526,065 | 6.40 |
| 2024-12-13 | 3,353,074 | +12.1% | 610,706 | 5.49 |
| 2024-11-29 | 2,992,076 | -18.0% | 1,041,406 | 2.87 |
| 2024-11-15 | 3,646,908 | +5.9% | 671,411 | 5.43 |
| 2024-10-31 | 3,442,275 | +0.4% | 233,546 | 14.74 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ACET volume is 26.8%, down 20.6 points over the last five sessions. Over the last 30 readings it ranged from 10.2% (28 October 2026) to 66.7% (5 October 2026). The latest reading is 7.5 points below the 30-session average of 34.2%, on 114K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 31K | 114K | 26.8% | 0 |
| 2026-10-30 | 14K | 99K | 13.7% | 0 |
| 2026-10-29 | 34K | 97K | 35.0% | 0 |
| 2026-10-28 | 9K | 90K | 10.2% | 1 |
| 2026-10-27 | 14K | 74K | 19.3% | 0 |
| 2026-10-26 | 43K | 90K | 47.3% | 0 |
| 2026-10-23 | 18K | 74K | 24.0% | 0 |
| 2026-10-22 | 19K | 73K | 26.1% | 0 |
| 2026-10-21 | 23K | 69K | 33.9% | 0 |
| 2026-10-20 | 13K | 57K | 23.3% | 0 |
| 2026-10-19 | 27K | 81K | 33.4% | 3,537 |
| 2026-10-16 | 42K | 90K | 47.0% | 5,845 |
| 2026-10-15 | 29K | 68K | 43.0% | 5,389 |
| 2026-10-14 | 53K | 171K | 31.3% | 0 |
| 2026-10-13 | 46K | 136K | 33.4% | 0 |
| 2026-10-12 | 14K | 40K | 34.3% | 2,138 |
| 2026-10-09 | 21K | 73K | 28.4% | 306 |
| 2026-10-08 | 36K | 101K | 35.4% | 163 |
| 2026-10-07 | 24K | 78K | 30.9% | 0 |
| 2026-10-06 | 15K | 56K | 27.0% | 0 |
| 2026-10-05 | 37K | 55K | 66.7% | 0 |
| 2026-10-02 | 27K | 78K | 34.3% | 0 |
| 2026-10-01 | 18K | 54K | 33.7% | 0 |
| 2026-09-30 | 36K | 119K | 30.5% | 0 |
| 2026-09-29 | 95K | 302K | 31.6% | 13,451 |
| 2026-09-28 | 379K | 860K | 44.0% | 98,781 |
| 2026-09-25 | 56K | 99K | 56.4% | 0 |
| 2026-09-24 | 69K | 165K | 42.0% | 0 |
| 2026-09-23 | 72K | 174K | 41.1% | 156 |
| 2026-09-22 | 16K | 36K | 43.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in ACET is 115 shares, down 13,687 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (11 February 2026) to 20,371 shares (11 March 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 115 | $5.11 | $588 |
| 2026-09-29 | 13,802 | $6.35 | $88K |
| 2026-09-24 | 298 | $8.49 | $3K |
| 2026-09-21 | 1,985 | $9.18 | $18K |
| 2026-08-21 | 3 | $9.38 | $28 |
| 2026-08-07 | 550 | $7.93 | $4K |
| 2026-08-04 | 8,537 | $9.24 | $79K |
| 2026-07-17 | 4 | $8.22 | $33 |
| 2026-06-30 | 21 | $8.56 | $180 |
| 2026-05-06 | 1 | $8.51 | $9 |
| 2026-04-23 | 558 | $8.31 | $5K |
| 2026-04-21 | 1,427 | $8.67 | $12K |
| 2026-04-20 | 3,843 | $8.22 | $32K |
| 2026-04-17 | 544 | $8.05 | $4K |
| 2026-03-26 | 2 | $6.81 | $14 |
| 2026-03-25 | 650 | $6.69 | $4K |
| 2026-03-17 | 8,482 | $7.17 | $61K |
| 2026-03-12 | 2,276 | $7.47 | $17K |
| 2026-03-11 | 20,371 | $7.53 | $153K |
| 2026-03-05 | 1,056 | $7.57 | $8K |
| 2026-03-02 | 1,129 | $7.25 | $8K |
| 2026-02-20 | 57 | $7.44 | $424 |
| 2026-02-13 | 3,076 | $6.72 | $21K |
| 2026-02-11 | 1 | $7.13 | $7 |
| 2026-02-03 | 99 | $7.98 | $790 |
| 2026-02-02 | 477 | $7.99 | $4K |
| 2026-01-26 | 1,459 | $8.44 | $12K |
| 2026-01-23 | 5,547 | $8.40 | $47K |
| 2026-01-22 | 2,830 | $8.07 | $23K |
| 2026-01-20 | 109 | $8.28 | $903 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ACET in the last 90 days. The most recent filings are listed below. Latest filing: Shah Rajeev M. (TenPercentOwner) on 2026-04-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-04-27 | Shah Rajeev M. | TenPercentOwner | Other transaction | 250K | price not stated in the filing | not stated | 933K |
| 2026-04-08 | OrbiMed Advisors Israel II Ltd | TenPercentOwner | Sell | 40K | $6.52 | $264K | 0 |
| 2026-04-08 | OrbiMed Advisors Israel II Ltd | TenPercentOwner | Sell | 33K | $6.29 | $205K | 0 |
| 2026-04-08 | ORBIMED ADVISORS LLC | 10% owner | Sell | 40K | $6.52 | $264K | 0 |
| 2026-04-08 | ORBIMED ADVISORS LLC | 10% owner | Sell | 33K | $6.29 | $205K | 0 |
| 2026-04-07 | OrbiMed Advisors Israel II Ltd | TenPercentOwner | Sell | 2K | $6.38 | $15K | 33K |
| 2026-04-07 | OrbiMed Advisors Israel II Ltd | TenPercentOwner | Sell | 29K | $6.53 | $191K | 35K |
| 2026-04-07 | ORBIMED ADVISORS LLC | 10% owner | Sell | 2K | $6.38 | $15K | 33K |
| 2026-04-07 | ORBIMED ADVISORS LLC | 10% owner | Sell | 29K | $6.53 | $191K | 35K |
| 2026-02-20 | RA Capital Healthcare Fund LP | TenPercentOwner | Buy | 75K | $7.27 | $543K | 1.2M |
| 2026-02-20 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Buy | 75K | $7.27 | $543K | 1.2M |
| 2026-02-19 | RA Capital Healthcare Fund LP | TenPercentOwner | Buy | 74K | $7.21 | $535K | 1.1M |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Buy | 74K | $7.21 | $535K | 1.1M |
| 2026-02-18 | RA Capital Healthcare Fund LP | TenPercentOwner | Buy | 75K | $7.04 | $525K | 1.0M |
| 2026-02-18 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Buy | 75K | $7.04 | $525K | 1.0M |
| 2026-01-24 | Aftab Blake | Chief Scientific Officer | Tax withholding | 535 | $8.44 | $5K | 3K |
| 2026-01-24 | Healey Don | Chief Technology Officer | Tax withholding | 535 | $8.44 | $5K | 3K |
| 2026-01-24 | Schor Chen | President & CEO | Tax withholding | 2K | $8.44 | $15K | 7K |
| 2026-01-24 | Harvey Brian Nicholas | Chief Financial Officer | Tax withholding | 546 | $8.44 | $5K | 5K |
| 2025-10-08 | ORBIMED ADVISORS LLC | 10% owner | Buy | 3.5M | $1.00 | $3.5M | 4.5M |
| 2025-10-08 | ORBIMED ADVISORS LLC | 10% owner | Buy | 1.5M | $1.00 | $1.5M | 9.0M |
| 2025-06-11 | Klickstein Lloyd | Director | Grant | 6K | $0.00 | $0 | 109K |
| 2025-06-11 | Chodakewitz Jeffrey | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2025-06-11 | DUBIN STEVE | Director | Grant | 6K | $0.00 | $0 | 23K |
| 2025-06-11 | Peng Katie | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2025-06-11 | Sinclair Andrew | Director | Grant | 6K | $0.00 | $0 | 18K |
| 2025-01-24 | Harvey Brian Nicholas | Chief Financial Officer | Tax withholding | 9K | $0.92 | $8K | 91K |
| 2025-01-24 | Aftab Blake | Chief Scientific Officer | Tax withholding | 6K | $0.92 | $6K | 56K |
| 2025-01-24 | Healey Don | Chief Technology Officer | Tax withholding | 9K | $0.92 | $8K | 64K |
| 2025-01-24 | Schor Chen | President & CEO | Tax withholding | 28K | $0.92 | $26K | 137K |
| 2024-06-05 | Sinclair Andrew | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2024-06-05 | Peng Katie | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2024-06-05 | Kauffman Michael | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2024-06-05 | Kauffman Michael | Director | Sell | 6K | $1.43 | $8K | 6K |
| 2024-06-05 | DUBIN STEVE | Director | Grant | 6K | $0.00 | $0 | 17K |
| 2024-06-05 | Jakobovits Aya | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2024-06-05 | Chodakewitz Jeffrey | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2024-06-05 | GORDON CARL L | Director,TenPercentOwner | Grant | 6K | $0.00 | $0 | 12K |
| 2024-01-25 | GORDON CARL L | Director,TenPercentOwner | Buy | 1.8M | $2.40 | $4.4M | 7.5M |
| 2024-01-25 | GORDON CARL L | Director,TenPercentOwner | Buy | 1.0M | $2.40 | $2.5M | 1.3M |
| 2024-01-25 | GORDON CARL L | Director,TenPercentOwner | Buy | 242K | $2.40 | $581K | 990K |
| 2024-01-25 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | Buy | 1.8M | $2.40 | $4.4M | 7.5M |
| 2024-01-25 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | Buy | 1.0M | $2.40 | $2.5M | 1.3M |
| 2024-01-25 | OrbiMed Advisors Israel II Ltd | Director,TenPercentOwner | Buy | 242K | $2.40 | $581K | 990K |
| 2024-01-24 | Schor Chen | President & CEO | Tax withholding | 15K | $2.40 | $37K | 138K |
| 2024-01-24 | Schor Chen | President & CEO | Grant | 70K | $0.00 | $0 | 209K |
| 2024-01-24 | Harvey Brian Nicholas | Chief Financial Officer | Tax withholding | 4K | $2.40 | $10K | 74K |
| 2024-01-24 | Harvey Brian Nicholas | Chief Financial Officer | Grant | 26K | $0.00 | $0 | 100K |
| 2024-01-24 | Healey Don | Chief Technology Officer | Tax withholding | 5K | $2.40 | $12K | 53K |
| 2024-01-24 | Healey Don | Chief Technology Officer | Grant | 20K | $0.00 | $0 | 72K |
| 2024-01-24 | Aftab Blake | Chief Scientific Officer | Tax withholding | 4K | $2.40 | $9K | 43K |
| 2024-01-24 | Aftab Blake | Chief Scientific Officer | Grant | 20K | $0.00 | $0 | 63K |
| 2024-01-24 | Galimi Francesco | SVP & Chief Medical Officer | Tax withholding | 5K | $2.40 | $12K | 76K |
| 2024-01-24 | Galimi Francesco | SVP & Chief Medical Officer | Grant | 26K | $0.00 | $0 | 102K |
| 2023-10-12 | Aftab Blake | Chief Scientific Officer | Tax withholding | 8K | $1.35 | $11K | 46K |
| 2023-10-02 | Schor Chen | President & CEO | Buy | 6K | $1.33 | $7K | 43K |
| 2023-10-02 | Schor Chen | President & CEO | Tax withholding | 23K | $1.37 | $32K | 154K |
| 2023-10-02 | Harvey Brian Nicholas | Chief Financial Officer | Tax withholding | 7K | $1.37 | $10K | 78K |
| 2023-10-02 | Healey Don | Chief Technology Officer | Tax withholding | 9K | $1.37 | $12K | 57K |
| 2023-10-02 | Galimi Francesco | SVP & Chief Medical Officer | Tax withholding | 8K | $1.37 | $11K | 80K |
| 2023-09-29 | Schor Chen | President & CEO | Sell | 6K | $1.36 | $7K | 177K |
| 2023-09-28 | Schor Chen | President & CEO | Buy | 6K | $1.42 | $8K | 182K |
| 2023-09-28 | Schor Chen | President & CEO | Sell | 6K | $1.42 | $8K | 38K |
| 2023-06-30 | DUBIN STEVE | Director | Buy | 5K | $2.40 | $12K | 11K |
| 2023-06-27 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | Buy | 125K | $2.09 | $261K | 1.0M |
| 2023-06-27 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | Buy | 250K | $2.09 | $523K | 647K |
| 2023-06-27 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | Buy | 442K | $2.09 | $924K | 5.7M |
| 2023-06-27 | ORBIMED ADVISORS LLC | Director,TenPercentOwner | Buy | 58K | $2.09 | $121K | 748K |
| 2023-06-27 | GORDON CARL L | Director,TenPercentOwner | Buy | 125K | $2.09 | $261K | 1.0M |
| 2023-06-27 | GORDON CARL L | Director,TenPercentOwner | Buy | 250K | $2.09 | $523K | 647K |
| 2023-06-27 | GORDON CARL L | Director,TenPercentOwner | Buy | 442K | $2.09 | $924K | 5.7M |
| 2023-06-27 | GORDON CARL L | Director,TenPercentOwner | Buy | 58K | $2.09 | $121K | 748K |
| 2023-06-01 | Sinclair Andrew | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-01 | DUBIN STEVE | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-01 | GORDON CARL L | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-01 | Jakobovits Aya | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-01 | Kauffman Michael | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-01 | Sanna Bastiano | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-06-01 | Chodakewitz Jeffrey | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2023-02-15 | Healey Don | Chief Technology Officer | Sell | 5K | $7.57 | $34K | 67K |
| 2023-02-10 | Healey Don | Chief Technology Officer | Sell | 10K | $7.98 | $84K | 71K |
| 2023-01-24 | Schor Chen | President & CEO | Grant | 86K | $0.00 | $0 | 177K |
| 2023-01-24 | Aftab Blake | Chief Scientific Officer | Grant | 26K | $0.00 | $0 | 54K |
| 2023-01-24 | Healey Don | Chief Technology Officer | Grant | 26K | $0.00 | $0 | 82K |
| 2023-01-24 | Harvey Brian Nicholas | Chief Financial Officer | Grant | 26K | $0.00 | $0 | 85K |
| 2023-01-24 | Galimi Francesco | SVP & Chief Medical Officer | Grant | 26K | $0.00 | $0 | 89K |
| 2022-11-10 | Schor Chen | President & CEO | Sell | 10K | $21.03 | $209K | 91K |
| 2022-11-10 | Schor Chen | President & CEO | Sell | 30K | $20.06 | $602K | 53K |
| 2022-11-10 | Aftab Blake | Chief Scientific Officer | Sell | 7K | $21.00 | $146K | 28K |
| 2022-11-07 | Schor Chen | President & CEO | Sell | 30K | $19.05 | $572K | 83K |
| 2022-11-03 | Schor Chen | President & CEO | Sell | 25K | $18.04 | $448K | 113K |
| 2022-11-02 | Schor Chen | President & CEO | Sell | 500 | $18.00 | $9K | 138K |
| 2022-10-19 | Aftab Blake | Chief Scientific Officer | Sell | 8K | $16.27 | $131K | 35K |
| 2022-10-13 | Aftab Blake | Chief Scientific Officer | Tax withholding | 8K | $15.92 | $126K | 43K |
| 2022-10-12 | Aftab Blake | Chief Scientific Officer | Sell | 2K | $15.40 | $25K | 51K |
| 2022-10-12 | Aftab Blake | Chief Scientific Officer | Exercise or conversion | 3K | $7.38 | $25K | 53K |
| 2022-10-04 | Healey Don | Chief Technology Officer | Tax withholding | 8K | $14.22 | $113K | 55K |
| 2022-10-04 | Galimi Francesco | SVP & Chief Medical Officer | Tax withholding | 8K | $14.22 | $113K | 62K |
| 2022-10-04 | Harvey Brian Nicholas | Chief Financial Officer | Tax withholding | 7K | $14.22 | $101K | 59K |
| 2022-10-04 | Schor Chen | President & CEO | Tax withholding | 21K | $14.22 | $303K | 101K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON3 Form 144 notices on file for ACET worth $1.2M at the prices reported; 0 in the last 90 days worth $0. Latest: OrbiMed Genesis Master Fund, L.P. filed on 2026-04-09 to sell 78,499 shares ($514K) from 2026-04-09.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-04-09 | OrbiMed Genesis Master Fund, L.P.Shareholder | 78K | $514K | 0.818% | 2026-04-09 | Themis Trading LLC |
| 2026-04-08 | OrbiMed Israel Partners II, L.P.Shareholder | 40K | $265K | 0.421% | 2026-04-08 | Themis Trading LLC |
| 2026-04-07 | OrbiMed Israel Partners Limited PartnershipShareholder | 64K | $413K | 0.669% | 2026-04-07 | Themis Trading LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of ACET in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Rajeev Shah at 9.9% of the class (935,486 shares), filed 2026-08-14 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-28 | 13G/Ano. 1 | Franklin Advisers, Inc.investment adviser, corporation | 724K | 7.7% | 2026-09-30 |
| 2026-10-28 | 13G/Ano. 1 | Franklin Templeton, Inc.parent holding company, corporation | 724K | 7.7% | 2026-09-30 |
| 2026-10-28 | 13G/Ano. 1 | Rupert H. Johnson, Jr.parent holding company, individual | 0 | 0.0% | 2026-09-30 |
| 2026-10-28 | 13G/Ano. 1 | Charles B. Johnsonparent holding company, individual | 0 | 0.0% | 2026-09-30 |
| 2026-10-23 | 13G | Zedek Lauren Marieindividual | 502K | 5.4% | 2026-10-19 |
| 2026-10-23 | 13G | Zedek Daniel Claytonindividual | 502K | 5.4% | 2026-10-19 |
| 2026-08-14 | 13G/Ano. 4 | Rajeev Shahparent holding company, individual | 935K | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | RA Capital Management, L.P.investment adviser, partnership | 935K | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | Peter Kolchinskyparent holding company, individual | 935K | 9.9% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | RA Capital Healthcare Fund, L.P.partnership | 935K | 9.9% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 1 | Woodline Partners LPinvestment adviser, partnership | 313K | 3.3% | 2026-03-31 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED ADVISORS LLCinvestment adviser | 845K | 8.8% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED CAPITAL GP V LLCother entity | 564K | 5.9% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED CAPITAL GP VI LLCother entity | 281K | 2.9% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | OrbiMed Genesis GP LLCother entity | 0 | 0.0% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED ADVISORS ISRAEL II LTDcorporation | 0 | 0.0% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED ISRAEL GP II, L.P.partnership | 0 | 0.0% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED ISRAEL GP LTD.corporation | 0 | 0.0% | 2026-04-08 |
| 2026-04-10 | 13D/Ano. 9 | ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIPpartnership | 0 | 0.0% | 2026-04-08 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS INTERNATIONAL, LPpartnership | 6K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL MANAGEMENT, LLCother entity | 6K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | KEVIN TANGindividual | 6K | 0.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS III, INCcorporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS IV, INCcorporation | 0 | 0.0% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 4 | TANG CAPITAL PARTNERS, LPpartnership | 0 | 0.0% | 2025-12-31 |
| 2026-01-29 | 13G | Franklin Resources, Inc.parent holding company, corporation | 627K | 6.5% | 2025-12-31 |
13F holders
Tracked managers holding ACET at their latest 13F. JSON3 of the 30 tracked managers held ACET at their latest 13F, $6.9M in total at quarter-end prices. Citadel Advisors is the largest at $3.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 0 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 433K | $3.7M | 0.00% | +51K |
| Renaissance Technologies | 2026-06-30 | 266K | $2.3M | 0.00% | +33K |
| Two Sigma Investments | 2026-06-30 | 97K | $837K | 0.00% | +54K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Adicet Bio in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Adicet Bio (ACET), SEC CIK 1720580, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-04-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-28.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-04-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1720580Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ACET is sold short?
521,883 shares were held short at the 2026-10-15 settlement, 2.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ACET's daily short volume?
On 2026-11-02, 30,574 of the 114,183 ACET shares reported to FINRA were sold short, 26.8% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ACET have fails to deliver?
The SEC's latest file shows 115 ACET shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are ACET insiders buying or selling?
No open-market insider trades were reported for ACET in the last 90 days. The most recent filings are listed below. Latest filing: Shah Rajeev M. (TenPercentOwner) on 2026-04-27.
Have ACET insiders filed to sell?
3 Form 144 notices on file for ACET worth $1.2M at the prices reported; 0 in the last 90 days worth $0. Latest: OrbiMed Genesis Master Fund, L.P. filed on 2026-04-09 to sell 78,499 shares ($514K) from 2026-04-09.
Who owns 5% or more of ACET?
11 holders report 5% or more of ACET in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Rajeev Shah at 9.9% of the class (935,486 shares), filed 2026-08-14 for an event on 2026-06-30.
Which tracked 13F managers own ACET?
3 of the 30 tracked 13F managers held ACET shares at their latest filing, $6.9M in all. The largest: Ken Griffin's Citadel Advisors (433K shares, $3.7M), Renaissance Technologies (266K shares, $2.3M), Two Sigma Investments (97K shares, $837K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.